YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Pfizer may merge off-patent drug business with Mylan

Posted online

Pfizer Inc. is considering a merger of its off-patent drug business with generic drugmaker Mylan, people familiar with the matter told The Wall Street Journal.

Under the proposal, Mylan shareholders would own more than 40% of the new entity and Pfizer shareholders would own the remainder.

Such a deal would create a global company that sells lower-priced pharmaceuticals.

Read more from The Wall Street Journal.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences